EUCTR2009-017351-96-BE进行中(未招募)不适用
A placebo controlled trial with Baclofen for the treatment of GERD patients with incomplete PPI response
Zleuven0 个研究点开始时间: 2009年12月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.18 to 75 years old.
- •2.History of GERD symptoms during PPI treatment, at least 3 times per week for 12 weeks.
- •3.Daily intake of PPI treatment 12 weeks prior to inclusion, with at least 8 weeks of b.i.d. therapy (2*20mg of omeprazole or equivalent).
- •4.Sexually active women of child bearing potential participating in the study must use a medically acceptable form of contraception. Medically acceptable forms of contraception include oral contraceptives, injectable or implantable methods, intrauterine devices, or properly used barrier contraception.
- •5.Subjects must be capable of understanding and be willing to provide signed and dated written voluntary informed consent before any protocol-specific screening procedures are performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Endoscopic signs of severe erosive esophagitis (= grade C, Los Angeles classification) on endoscopy performed during PPI treatment in the 6 months prior to screening.
- •2.Systemic diseases, known to affect esophageal motility.
- •3.Surgery in thorax or in the upper part of the abdomen.
- •4.Treatment with baclofen prior to the start of the study.
- •5.Regular use of medications such as: anticholinergics, tricycle antidepressants.
- •6.Significant neurological, respiratory, hepatic, renal, haematological, cardiovascular, metabolic or gastroinestinal cerebrovascular disease as judged by the investigator
- •7.Absence of PPI intake for at least 2 consecutive days in the 2 weeks prior to the screening.
- •8.Pregnancy or breast feeding.
- •9.History of poor compliance. History of/or current psychiatric illness that would interfere with ability to comply with protocol requirements or give informed consent. (well-compensated depression is allowed).
- •10.History of alcohol or drug abuse that would interfere with ability to comply with protocol requirements.
研究者
相似试验
进行中(未招募)
1 期
Study investigating the effect of baclofen in patients with postprandial regurgitation or belchingRumination syndrome and supragastric belchingMedDRA version: 14.0Level: LLTClassification code 10039292Term: Rumination disorderSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.0Level: LLTClassification code 10004222Term: BelchingSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-002745-35-BEZLeuven20
招募中
3 期
To examine how well Baclofen and Naltrexone work as medications in individuals with alcohol addiction and withdrawal symptoms.CTRI/2024/06/069491Rahul
尚未招募
4 期
A study to compare whether oral baclofen or oral tizanidine is better in patients presenting with tightness of the upper limb after stroke.CTRI/2024/03/064651Jalpaiguri Government Medical College and Hospital
撤回
2 期
A Study of Baclofen ERCocaine DependenceNCT02003664University of Pennsylvania
已完成
2 期
Baclofen for Treating Anxiety and AlcoholismAlcohol Drinking Related ProblemsAlcohol DrinkingAlcohol DependenceAnxiety DisorderAlcoholismNCT01751386National Institute on Alcohol Abuse and Alcoholism (NIAAA)39
